Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2006
MelanomaAlan N Houghton, Daniel G Coit, Adil Daud, et al.
The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Molecular Cancer|February 21, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 4, 2006
MelanomaAlan N Houghton, Daniel G Coit, Adil Daud, et al.
The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Molecular Cancer|February 21, 2024
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanomaValentin Feichtenschlager, Linan Chen, Yixuan James Zheng, et al.
Pageof 11